The company has a Growth Grade of B and a Value Grade of B. TGT has an overall grade of A, which is a Strong Buy Rating in our POWR Ratings system. The company is also increasing its private-label offerings and its Food & Beverage segment. One example is its partnership with Ulta. Plus, its partnerships should enhance its product selection. Its same-day services such as Drive Up & Pick Up are bringing more customers. This is expected to continue for some time. The company is benefiting from a trend in consumers shopping at discount stores. In its most recent quarterly report, the company reported market share gains in all of its merchandise categories (Apparel, Beauty, Electronics, Essentials and Food & Beverage) due to strong demand It has been focused on increasing the appeal of its store through enhancing its digital capabilities and expanding its same-day fulfillment options. The company currently has around 1,900 stores in the U.S. TGT is just about as well-known as JNJ and is one of the largest discount retailers in the country. Д¬lick here to checkout our Healthcare Sector Report for 2021 You can see other top stocks in this industry by clicking here. JNJ is ranked #1 in the Medical вЂ“ Pharmaceutical industry. We also provide grades Momentum, Stability, Sentiment, and Quality grades for JNJ. The stock currently has a forward P/E of only 17.12 and is trading 14% below its average analyst price target. Earnings are expected to rise 35.3% year over year in the current quarter, and revenues are forecasted to grow 25.9% over the same time frame. The company has a Growth Grade of B, which isnвЂ™t surprising as earnings have grown an average of 130.7% per year over the past three years. JNJ has an overall rating of A, which translates into a Strong Buy in our POWR Ratings system. The company also has a significant market share in the medical device industry with orthopedic and Ethicon Endo-SurgeryвЂ™s surgical devices. Plus, many of its key drugs and pipeline drugs are specialty treatments with strong pricing power and lower regulatory hurdles for approval.

This includes immunology drugs such as Remicade, Stelara, and Tremfya and cancer treatments Darzalex and Imbruvica. The pharmaceuticals division also has the best future growth potential.ДЇor instance, the company offers several industry-leading drugs.

JNJвЂ™s pharmaceutical segment makes up close to 50% of total revenue. The company has generated further interest by being of the providers approved for the COVID-19 vaccine. The company is well known for providing pharmaceuticals, medical devices, as well as consumer health products. JNJ is one of, if not the most recognizable, names in healthcare. This makes sure we see the best growth stocks at low valuations, and why I am recommending investors consider Johnson & Johnson ( JNJ ), Target Corporation ( TGT ), Dell Technologies Inc ( DELL ), Agilent Technologies, Inc. So, I ran a screen for top undervalued growth stocks in our POWR Rating system for Buy-rated stocks with a Growth Grade of A or B and a Value Grade of A or B. This way, we get the best of both worlds. With many of the top growth stocks seeing their shares pullback in the winter, now is a great time to invest in growth at a lower valuation. The value trade is taking a breather as improving economic conditions look already priced in. When investors learned of the efficacy of the coronavirus vaccines at the end of the year, a rotation out of growth stocks took place in the market, as a rapidly improving economy benefits more cyclical and value names.Д«ut it appears growth stocks are back in favor as the SPGY gained 6.8% last month. The SPDR S&P 500 Growth ETF ( SPYG ) gained 78.3% from March 23rd to December 31st. Growth stocks soared in 2020, with tech shares leading the way.

Back in focus jnj